Regenerative Medical Technology (RMTG) Depreciation & Amortization (CF) (2019 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Depreciation & Amortization (CF) of $97694.0 for Q1 2026, up 88.55% year-over-year from $51814.0 in Q1 2025, and down 0.66% quarter-over-quarter from $98343.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Regenerative Medical Technology's Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $97694.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 88.55% year-over-year to $97694.0; the TTM figure through Mar 2026 stood at $326947.0 (up 66.98% YoY), while the FY2025 annual figure was $281067.0, up 27.43% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $97694.0, down from $98343.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $98667.0 in Q3 2023, with the low at -$27812.0 in Q4 2024.
- The 5-year median for Depreciation & Amortization (CF) is $57875.0 (2023), against an average of $62480.1.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) surged 17462.5% in 2022, then plunged 128.69% in 2024.
- Regenerative Medical Technology's Depreciation & Amortization (CF) stood at $51155.0 in 2022, then surged by 89.49% to $96932.0 in 2023, then slumped by 128.69% to -$27812.0 in 2024, then surged by 453.6% to $98343.0 in 2025, then declined by 0.66% to $97694.0 in 2026.
- Business Quant data shows RMTG's Depreciation & Amortization (CF) at $97694.0 in Q1 2026, $98343.0 in Q4 2025, and $76078.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 97,694.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97,694.00 |
| Mar 31, 2026 | 97,694.00 |
| Dec 31, 2025 | 98,343.00 |
| Dec 31, 2025 | 98,343.00 |
| Sep 30, 2025 | 76,078.00 |
| Sep 30, 2025 | 76,078.00 |
| Jun 30, 2025 | 54,832.00 |
| Jun 30, 2025 | 54,832.00 |
| Mar 31, 2025 | 51,814.00 |
| Mar 31, 2025 | 51,814.00 |
| Dec 31, 2024 | -27,812.00 |
| Dec 31, 2024 | -27,812.00 |
| Sep 30, 2024 | 88,828.00 |
| Sep 30, 2024 | 88,828.00 |
| Jun 30, 2024 | 82,971.00 |
| Jun 30, 2024 | 82,971.00 |
| Mar 31, 2024 | 76,572.00 |
| Mar 31, 2024 | 76,572.00 |
| Dec 31, 2023 | 96,932.00 |
| Dec 31, 2023 | 96,932.00 |